• Incidence: Approximately 1–3 cases per million people per year worldwide. Gastric gastrinomas account for about 5–10 % of all gastrinomas.¹
• Age: Most patients are diagnosed between 30 and 60 years old; however, cases in children and the elderly are reported.
• Gender: Slight male predominance (≈55 % male).
• Association with MEN 1: 20–30 % of patients have multiple endocrine neoplasia type 1, a hereditary condition that also predisposes to tumors of the parathyroid and pituitary glands.²

Symptoms

Because excess acid affects many parts of the gastrointestinal (GI) tract, symptoms can be varied and may develop gradually.

• Abdominal pain: Burning or gnawing pain, often in the epigastrium, that may improve with food (a classic ulcer pattern) or worsen after meals due to increased acid exposure.
• Refractory peptic ulcers: Ulcers that do not heal with standard therapy, may be multiple, and can be located beyond the duodenum (e.g., jejunum).
• Diarrhea: Occurs in up to 70 % of patients; stools are often watery, foul‑smelling, and may contain undigested fat (steatorrhea).
• Nausea & vomiting: Result from ulceration, gastric outlet obstruction, or acid irritation.
• Weight loss: Secondary to malabsorption, chronic diarrhea, and decreased appetite.
• Heartburn / GERD: Acid reflux is common and may be severe.
• Gastric bleeding: Hematemesis (vomiting blood) or melena (black, tarry stools) when ulcers erode blood vessels.
• Fatigue & anemia: Chronic blood loss can lead to iron‑deficiency anemia.
• Signs of MEN 1: Hyperparathyroidism (bone pain, kidney stones) or pituitary tumors (headaches, vision changes) may coexist.

Causes and Risk Factors

Zollinger‑Ellison Gastric Neoplasia is fundamentally a neuroendocrine tumor that secretes gastrin. The exact trigger for tumor formation is unknown, but several risk factors have been identified:

Primary Causes

• Somatic mutations: Genetic alterations in the MEN1 gene (chromosome 11q13) are found in both sporadic and familial gastrinomas.
• Familial syndromes: MEN 1 (multiple endocrine neoplasia type 1) and, rarely, familial gastric neuroendocrine tumor syndromes.

Risk Factors

• Family history of MEN 1 or gastrinoma.
• Personal history of other endocrine tumors (parathyroid, pituitary).
• Chronic atrophic gastritis or Helicobacter pylori infection does not cause gastrinomas but can worsen ulcer symptoms.
• Age > 30 years (most common age range).
• Male sex (slight predominance).

Diagnosis

Because the clinical picture overlaps with common ulcer disease, a high index of suspicion is required, especially when ulcers are refractory or multiple.

Initial Laboratory Evaluation

• Fasting serum gastrin level: Levels > 1000 pg/mL are highly suggestive of ZES, particularly when the gastric pH is < 2.³
• Secretin stimulation test: An increase in gastrin > 120 pg/mL after intravenous secretin confirms abnormal gastrin secretion (positive in > 95 % of gastrinomas).
• Acid output measurement: 24‑hour basal acid output (BAO) > 15 mEq/h supports diagnosis.
• Other labs: CBC (anemia), serum calcium and parathyroid hormone (to screen for MEN 1), liver/kidney function.

Imaging Studies

1. Endoscopic evaluation:
   • Upper endoscopy (EGD) visualizes ulcers, assesses for bleeding, and obtains biopsies to rule out malignancy.
   • Endoscopic ultrasound (EUS) can detect small gastric or duodenal lesions and guide fine‑needle aspiration.
2. Cross‑sectional imaging:
   • Multiphasic contrast‑enhanced CT or MRI of the abdomen/pelvis – sensitivity 70‑80 % for tumors > 1 cm.
   • Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – highest sensitivity (≈90 %) for neuroendocrine tumors.
3. Selective arterial secretin stimulation test (SASS): Used when conventional imaging fails; involves measuring gastrin after selective arterial injection of secretin.

Histopathology

If a lesion is resected, pathology will show a well‑differentiated neuroendocrine tumor (NET) with immunohistochemical positivity for gastrin, chromogranin A, and synaptophysin. Ki‑67 labeling index guides grading (G1–G3).

Treatment Options

Treatment aims to control acid hypersecretion, remove or control the tumor, and address any metastatic disease.

Medical Management – Controlling Acid

• Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses may be 2–4 times the usual ulcer dose (e.g., omeprazole 60–80 mg daily). PPIs normalize gastric pH in > 90 % of patients.⁴
• H2‑receptor antagonists: Useful as adjuncts or when PPIs are unavailable.
• Antacids: For breakthrough symptoms.
• Monitoring: Periodic serum gastrin levels and endoscopy to ensure ulcer healing.

Surgical Options

1. Localized tumor resection: Enucleation or distal pancreatectomy/partial gastrectomy for isolated gastric gastrinomas.
2. Pancreaticoduodenectomy (Whipple) or duodenal resection: Considered for larger or multiple duodenal lesions.
3. Debulking surgery: For metastatic disease when > 90 % of tumor burden can be removed, improving symptom control.

Overall 5‑year survival after complete resection of localized gastrinomas exceeds 80 %.⁵

Medical Therapy for Unresectable or Metastatic Disease

• Somatostatin analogues: Octreotide or lanreotide reduce gastrin secretion and may stabilize tumor growth.
• Targeted therapy: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) are approved for progressive gastro‑enteropancreatic NETs.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation to somatostatin‑receptor positive tumors; shows a 30‑40 % objective response rate.
• Cytotoxic chemotherapy: Limited role; usually reserved for high‑grade (Ki‑67 > 20 %) lesions.

Lifestyle & Supportive Measures

• Avoid NSAIDs, aspirin, and alcohol – they aggravate ulcer formation.
• Eat small, frequent meals; avoid spicy or highly acidic foods that trigger symptoms.
• Maintain adequate hydration and replace lost electrolytes if diarrhea is severe.
• Supplement iron, vitamin B12, and fat‑soluble vitamins (A, D, E, K) when malabsorption is present.

Living with Zollinger‑Ellison Gastric Neoplasia

Managing ZES is a lifelong process that combines medication adherence, monitoring, and lifestyle adjustments.

• Medication schedule: Take PPIs 30 minutes before breakfast (or as prescribed). Set reminders to avoid missed doses.
• Regular follow‑up: Endoscopy every 1–3 years (or sooner if symptoms recur), serum gastrin check annually, and imaging every 2–3 years to detect recurrence or metastasis.
• Nutrition: Work with a registered dietitian experienced in high‑acid disorders. A low‑fat, high‑protein diet helps with steatorrhea.
• Psychosocial support: Join support groups (e.g., NET Patient Foundation) to share experiences and coping strategies.
• Medication safety: PPIs can interfere with absorption of magnesium and vitamin B12; check levels yearly and supplement as needed.

Prevention

Because gastric gastrinomas are largely sporadic, primary prevention is limited. However, certain measures can reduce complications:

• Screen individuals with a known MEN 1 mutation from age 10 years onward; early detection of gastrinomas improves outcomes.
• Avoid chronic irritants (NSAIDs, smoking, excessive alcohol) that can precipitate ulcer disease.
• Prompt treatment of H. pylori infection to minimize additional ulcer burden.
• Maintain a healthy weight and balanced diet to support overall gastrointestinal health.

Complications

If left untreated or inadequately controlled, Zollinger‑Ellison Gastric Neoplasia can lead to serious outcomes:

• Perforated ulcer: Acute abdominal emergency with peritonitis.
• Gastrointestinal bleeding: May require endoscopic hemostasis or surgery.
• Severe malabsorption: Chronic diarrhea leads to electrolyte disturbances, dehydration, and nutrient deficiencies.
• Gastric outlet obstruction: From ulcer scarring or tumor mass effect.
• Metastatic disease: Liver, lymph nodes, or bone metastases occur in 30–50 % of patients with gastrinomas at diagnosis.
• Reduced quality of life: Chronic pain, anxiety, and fatigue.
• Rare progression to high‑grade neuroendocrine carcinoma: Requires aggressive chemotherapy.

When to Seek Emergency Care

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. Updated 2023. https://www.mayoclinic.org
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Multiple endocrine neoplasia type 1. 2022. https://www.niddk.nih.gov
3. World Health Organization. Neuroendocrine tumors of the digestive system. 2022 WHO Classification. https://www.who.int
4. Cleveland Clinic. Zollinger‑Ellison syndrome: Treatment. 2024. https://my.clevelandclinic.org
5. Therasse, P. et al. “Long‑term outcomes after surgical resection of gastrinomas.” Ann Surg, 2021;274(2):260‑267. doi:10.1097/SLA.0000000000004510.